Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-(Carboxyvin-2-Yl)Phenylboronic Acid is a synthetic small molecule containing both a boronic acid and carboxylic acid functional group, with the chemical formula C9H9BO4 and molecular weight of approximately 192 g/mol[1][2][5]. It is primarily studied as an experimental compound and has been used in structural biology as an inhibitor of beta-lactamase enzymes, such as AmpC beta-lactamase from Escherichia coli. The mechanism involves binding to the active site of the enzyme, mimicking transition states or intermediates in enzymatic reactions, thereby inhibiting its function[8][10]. This makes it relevant for research into overcoming bacterial resistance to beta-lactam antibiotics. There are no known approved therapeutic indications or marketed formulations for this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-(carboxyvin-2-yl)phenylboronic acid.